Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03576183 · ClinicalTrials.gov registry record · Phase 2
Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701
A Phase 2 study, sponsored by Valneva Austria.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT03576183 is a Phase 2 study that has completed, run by Valneva Austria. The registered enrollment target is 34 participants.
The verdict
NCT03576183, a Phase 2 study, has completed, sponsored by Valneva Austria.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a single-center, double-blind, placebo-controlled, Phase II vaccination and challenge study designed to confirm a human challenge model with E. coli strain LSN03-016011/A.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL VLA1701
- OTHER Challenge Strain
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2018-06-04 |
| Est. Completion | 2018-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03576183
The ClinicalTrials.gov registry entry for NCT03576183 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Valneva Austria, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03576183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03576183 about?
NCT03576183 is a clinical study titled "Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701". This is a single-center, double-blind, placebo-controlled, Phase II vaccination and challenge study designed to confirm a human challenge model with E. coli strain LSN03-016011/A.
What is the current status of trial NCT03576183?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2018-06-04. Estimated completion is 2018-11-30.
What interventions are being tested in trial NCT03576183?
The interventions under investigation include: Placebo (BIOLOGICAL), VLA1701 (BIOLOGICAL), Challenge Strain (OTHER).
Who is sponsoring clinical trial NCT03576183?
This trial is sponsored by Valneva Austria, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.